Business Description
Intercept Pharmaceuticals Inc
NAICS : 325412
SIC : 2834
ISIN : US45845P1084
Compare
Compare
Traded in other countries / regions
I4P.GermanyICPT.MexicoICPT.USA IPO Date
2012-10-18Description
Intercept Pharmaceuticals Inc is a biotech company focused on developing and commercializing novel therapeutics to treat progressive non-viral liver diseases. Obeticholic acid, or OCA, is an agonist of the farnesoid X receptor. OCA was approved as Ocaliva to treat primary biliary cirrhosis in 2016 and is being developed for a variety of chronic liver diseases, including nonalcoholic steatohepatitis, or NASH.
Financial Strength
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 1.3 | |||||
| Equity-to-Asset | 0.13 | |||||
| Debt-to-Equity | 4.96 | |||||
| Debt-to-EBITDA | -2.12 | |||||
| Piotroski F-Score | 5/9 | |||||
| Altman Z-Score | -5.21 | |||||
| Beneish M-Score | 0.5 | |||||
| WACC vs ROIC | ||||||
Growth Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 2 | |||||
| 3-Year EBITDA Growth Rate | 21.6 | |||||
| 3-Year EPS without NRI Growth Rate | 22 | |||||
| 3-Year FCF Growth Rate | 52.4 | |||||
| 3-Year Book Growth Rate | 12.6 | |||||
| Future 3-5Y Total Revenue Growth Rate | 13.5 |
Momentum Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 25.33 | |||||
| 9-Day RSI | 26.57 | |||||
| 14-Day RSI | 29.35 | |||||
| 6-1 Month Momentum % | 18.34 | |||||
| 12-1 Month Momentum % | 3.5 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 2.37 | |||||
| Quick Ratio | 2.37 | |||||
| Cash Ratio | 2.09 | |||||
| Days Sales Outstanding | 38.53 | |||||
| Days Payable | 5223.1 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -8.1 |
Profitability Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 99.67 | |||||
| Operating Margin % | -24.83 | |||||
| Net Margin % | 70.27 | |||||
| ROE % | Neg. Equity | |||||
| ROA % | 39.51 | |||||
| ROIC % | -64.8 | |||||
| ROC (Joel Greenblatt) % | -5257.82 | |||||
| ROCE % | -47.52 | |||||
| Years of Profitability over Past 10-Year | 1 |
GF Value Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 1.63 | |||||
| Price-to-Owner-Earnings | 1.98 | |||||
| PS Ratio | 1.26 | |||||
| PB Ratio | 6.36 | |||||
| Price-to-Tangible-Book | 6.38 | |||||
| EV-to-EBIT | -2.08 | |||||
| EV-to-Forward-EBIT | -4.07 | |||||
| EV-to-EBITDA | -2.08 | |||||
| EV-to-Forward-EBITDA | -4.08 | |||||
| EV-to-Revenue | 1.11 | |||||
| EV-to-Forward-Revenue | 1.02 | |||||
| EV-to-FCF | -5.56 | |||||
| Price-to-Median-PS-Value | 0.07 | |||||
| Price-to-Net-Current-Asset-Value | 7.99 | |||||
| Earnings Yield (Greenblatt) % | -48.08 |
Balance Sheet Breakdown
Cashflow Statement Breakdown
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Annualized Return %
Total Annual Return %
Intercept Pharmaceuticals Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 282.614 | ||
| EPS (TTM) (€) | 6.45 | ||
| Beta | 0.74 | ||
| Volatility % | 83.09 | ||
| 14-Day RSI | 29.35 | ||
| 14-Day ATR (€) | 0.854732 | ||
| 20-Day SMA (€) | 13.24175 | ||
| 12-1 Month Momentum % | 3.5 | ||
| 52-Week Range (€) | 8.164 - 20 | ||
| Shares Outstanding (Mil) | 41.69 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Intercept Pharmaceuticals Inc Filings
| Document | Form | Filing Date | ||
|---|---|---|---|---|
| No Filing Data | ||||
Intercept Pharmaceuticals Inc Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Intercept Pharmaceuticals Inc Frequently Asked Questions
What is Intercept Pharmaceuticals Inc(FRA:I4P)'s stock price today?
The current price of FRA:I4P is €8.86. The 52 week high of FRA:I4P is €20.00 and 52 week low is €8.16.
When is next earnings date of Intercept Pharmaceuticals Inc(FRA:I4P)?
The next earnings date of Intercept Pharmaceuticals Inc(FRA:I4P) is 2023-08-03 Est..
Does Intercept Pharmaceuticals Inc(FRA:I4P) pay dividends? If so, how much?
Intercept Pharmaceuticals Inc(FRA:I4P) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
